Patent intelligence · US
US 11479599
Antibodies against SARS-CoV-2 and methods of using the same
Antibodies against SARS-CoV-2 and methods of using the same
Patent details — US 11479599
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 25, 2022
- Expiration
- Oct 20, 2042
- Applicant
- Vir Biotechnology, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61P, A61P31/14
Quick answer
US 11479599 (Antibodies against SARS-CoV-2 and methods of using the same) is held by Vir Biotechnology, Inc.. Status: granted. Granted Oct 25, 2022. Expires Oct 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vir Biotechnology, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61P, A61P31/14
More from Vir Biotechnology, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12404318
Combination HBV therapy
granted -
US 11628215
HIV vaccines comprising one or more population episensus antigens
granted -
US 11554168
HIV vaccines comprising one or more population episensus antigens
granted -
US 11168128
Antibodies against SARS-CoV-2 and methods of using the same
granted -
US 10894078
HIV vaccines comprising one or more population episensus antigens
granted
Frequently asked questions
What is US patent 11479599?
US 11479599 (Antibodies against SARS-CoV-2 and methods of using the same) is held by Vir Biotechnology, Inc.. Status: granted. Granted Oct 25, 2022. Expires Oct 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11479599?
Vir Biotechnology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 11479599 expire?
Our index shows an expiration date of Oct 20, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.